NewAmsterdam Pharma Company N.V. (NAMS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Naarden, Netherlands. The current CEO is Michael Harvey Davidson Facp..
NAMS has IPO date of 2021-02-09, 68 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $3.96B.
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Naarden, the Netherlands, dedicated to developing treatments for metabolic diseases. The company's lead investigational candidate, obicetrapib, is a novel selective inhibitor of Cholesteryl Ester Transfer Protein (CETP) that has demonstrated clinical efficacy in reducing low-density lipoprotein cholesterol (LDL-C) while substantially increasing high-density lipoprotein cholesterol (HDL-C). This dual mechanism addresses a significant unmet medical need in lipid management and cardiovascular disease prevention. NewAmsterdam is focused on advancing obicetrapib through clinical development to improve patient outcomes in metabolic disease populations.
